300 related articles for article (PubMed ID: 20682373)
1. Potential anticancer properties of bisphosphonates.
Neville-Webbe HL; Gnant M; Coleman RE
Semin Oncol; 2010 Jun; 37 Suppl 1():S53-65. PubMed ID: 20682373
[TBL] [Abstract][Full Text] [Related]
2. Bisphosphonates and RANK ligand inhibitors for the treatment and prevention of metastatic bone disease.
Neville-Webbe HL; Coleman RE
Eur J Cancer; 2010 May; 46(7):1211-22. PubMed ID: 20347292
[TBL] [Abstract][Full Text] [Related]
3. Bisphosphonates in breast cancer: clinical activity and implications of preclinical data.
Aft R
Clin Adv Hematol Oncol; 2011 Mar; 9(3):194-205. PubMed ID: 21475125
[TBL] [Abstract][Full Text] [Related]
4. Anticancer properties of zoledronic acid.
Green J; Lipton A
Cancer Invest; 2010 Nov; 28(9):944-57. PubMed ID: 20879838
[TBL] [Abstract][Full Text] [Related]
5. Bisphosphonates: preclinical review.
Green JR
Oncologist; 2004; 9 Suppl 4():3-13. PubMed ID: 15459425
[TBL] [Abstract][Full Text] [Related]
6. Clinical value of bisphosphonates in cancer therapy.
Lüftner D; Henschke P; Possinger K
Anticancer Res; 2007; 27(4A):1759-68. PubMed ID: 17649770
[TBL] [Abstract][Full Text] [Related]
7. New results from the use of bisphosphonates in cancer patients.
Coleman R; Gnant M
Curr Opin Support Palliat Care; 2009 Sep; 3(3):213-8. PubMed ID: 19561507
[TBL] [Abstract][Full Text] [Related]
8. [Antitumour effects of bisphosphonates in breast cancer].
van de Ven S; Kroep JR; Hamdy NA; Sleeboom HP; Nortier HW
Ned Tijdschr Geneeskd; 2010; 154():A1951. PubMed ID: 21083955
[TBL] [Abstract][Full Text] [Related]
9. Bisphosphonates as anticancer therapy for early breast cancer.
Mahtani R; Jahanzeb M
Clin Breast Cancer; 2010 Oct; 10(5):359-66. PubMed ID: 20920980
[TBL] [Abstract][Full Text] [Related]
10. Antitumor effects and anticancer applications of bisphosphonates.
Morgan G; Lipton A
Semin Oncol; 2010 Oct; 37 Suppl 2():S30-40. PubMed ID: 21111246
[TBL] [Abstract][Full Text] [Related]
11. The antitumor potential of bisphosphonates.
Clézardin P
Semin Oncol; 2002 Dec; 29(6 Suppl 21):33-42. PubMed ID: 12584693
[TBL] [Abstract][Full Text] [Related]
12. Are bisphosphonates the suitable anticancer drugs for the elderly?
Santini D; Fratto ME; Galluzzo S; Vincenzi B; Tonini G
Crit Rev Oncol Hematol; 2009 Jan; 69(1):83-94. PubMed ID: 18692400
[TBL] [Abstract][Full Text] [Related]
13. Exploring the anti-tumour activity of bisphosphonates in early breast cancer.
Winter MC; Holen I; Coleman RE
Cancer Treat Rev; 2008 Aug; 34(5):453-75. PubMed ID: 18423992
[TBL] [Abstract][Full Text] [Related]
14. Management of castration-resistant prostate cancer: bisphosphonates and emerging therapies.
Saad F; Colombel M
Expert Rev Anticancer Ther; 2010 Dec; 10(12):1991-2002. PubMed ID: 21110764
[TBL] [Abstract][Full Text] [Related]
15. Emerging role of bisphosphonates in the clinic--antitumor activity and prevention of metastasis to bone.
Lipton A
Cancer Treat Rev; 2008; 34 Suppl 1():S25-30. PubMed ID: 18486347
[TBL] [Abstract][Full Text] [Related]
16. On the horizon: can bisphosphonates prevent bone metastases?
Coleman R
Breast; 2007 Dec; 16 Suppl 3():S21-7. PubMed ID: 17988867
[TBL] [Abstract][Full Text] [Related]
17. Bisphosphonates for cancer patients: why, how, and when?
Body JJ; Mancini I
Support Care Cancer; 2002 Jul; 10(5):399-407. PubMed ID: 12136223
[TBL] [Abstract][Full Text] [Related]
18. Bisphosphonates and cancer-induced bone disease: beyond their antiresorptive activity.
Clézardin P; Ebetino FH; Fournier PG
Cancer Res; 2005 Jun; 65(12):4971-4. PubMed ID: 15958534
[TBL] [Abstract][Full Text] [Related]
19. Bisphosphonates for the prevention of bone metastases.
Coleman RE
Semin Oncol; 2002 Dec; 29(6 Suppl 21):43-9. PubMed ID: 12584694
[TBL] [Abstract][Full Text] [Related]
20. Bisphosphonates and their impact on disseminated tumor cells in early stage breast cancer.
Li J; Rugo HS
Breast Dis; 2011; 33(2):83-92. PubMed ID: 22142661
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
